Bioventus (BVS) Asset Writedowns and Impairment (2020 - 2026)

Bioventus' Asset Writedowns and Impairment history runs 7 years deep, the most recent figure standing at $230000.0 for Q1 2026.

• Quarterly Asset Writedowns and Impairment fell 64.62% year-over-year to $230000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$420000.0 (down 101.21% YoY) and the FY2024 annual result came in at -$434000.0, down 100.55% from the prior year.
• Asset Writedowns and Impairment was $230000.0 for Q1 2026 at Bioventus, up from -$944000.0 in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $78.6 million in Q2 2023 and bottomed at -$976000.0 in Q1 2024.
• A 5-year average of $9.6 million and a median of $650000.0 in 2025 frame the typical range for Asset Writedowns and Impairment.
• Annual changes were most pronounced in 2023 — Asset Writedowns and Impairment soared 6724.22% — and 2025, when it slumped 627.37%.
• Bioventus' Asset Writedowns and Impairment stood at $10.3 million in 2022, then jumped by 664.37% to $78.6 million in 2023, then tumbled by 99.77% to $179000.0 in 2024, then slumped by 627.37% to -$944000.0 in 2025, then soared by 124.36% to $230000.0 in 2026.
• Business Quant data shows BVS's Asset Writedowns and Impairment at $230000.0 in Q1 2026, -$944000.0 in Q4 2025, and $101000.0 in Q3 2025.